 |
PDBsum entry 3eb1
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of ptp1b inhibitors.
|
 |
|
Authors
|
 |
S.Liu,
L.F.Zeng,
L.Wu,
X.Yu,
T.Xue,
A.M.Gunawan,
Y.Q.Long,
Z.Y.Zhang.
|
 |
|
Ref.
|
 |
J Am Chem Soc, 2008,
130,
17075-17084.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
There has been considerable interest in protein tyrosine phosphatase 1B (PTP1B)
as a therapeutic target for diabetes, obesity, as well as cancer. Identifying
inhibitory compounds with good bioavailability is a major challenge of drug
discovery programs targeted toward PTPs. Most current PTP active site-directed
pharmacophores are negatively charged pTyr mimetics which cannot readily enter
the cell. This lack of cell permeability limits the utility of such compounds in
signaling studies and further therapeutic development. We identify aryl
diketoacids as novel pTyr surrogates and show that neutral amide-linked aryl
diketoacid dimers also exhibit excellent PTP inhibitory activity. Kinetic
studies establish that these aryl diketoacid derivatives act as noncompetitive
inhibitors of PTP1B. Crystal structures of ligand-bound PTP1B reveal that both
the aryl diketoacid and its dimeric derivative bind PTP1B at the active site,
albeit with distinct modes of interaction, in the catalytically inactive, WPD
loop open conformation. Furthermore, dimeric aryl diketoacids are cell permeable
and enhance insulin signaling in hepatoma cells, suggesting that targeting the
inactive conformation may provide a unique opportunity for creating active
site-directed PTP1B inhibitors with improved pharmacological properties.
|
 |
|
|
|
|
 |